Bimekizumab versus Adalimumab in Plaque Psoriasis.

Tytuł:: Bimekizumab versus Adalimumab in Plaque Psoriasis.
Autorzy:: Griffith SK; Medical College of Georgia at Augusta University, Augusta, GA.
Ahn GS; University of California, San Diego, La Jolla, CA.
Wu JJ; Dermatology Research and Education Foundation, Irvine, CA .
Źródło:: The New England journal of medicine [N Engl J Med] 2021 Sep 16; Vol. 385 (12), pp. 1149-1150.
Typ publikacji:: Letter; Comment
Język:: English
Imprint Name(s):: Original Publication: Boston, Massachusetts Medical Society.
MeSH Terms:: Antibodies, Monoclonal, Humanized*/therapeutic use
Psoriasis*/drug therapy
Adalimumab/therapeutic use ; Humans
Substance Nomenclature:: 0 (Antibodies, Monoclonal, Humanized)
09495UIM6V (bimekizumab)
FYS6T7F842 (Adalimumab)
Entry Date(s):: Date Created: 20210915 Date Completed: 20210920 Latest Revision: 20210920
Update Code:: 20240105
DOI:: 10.1056/NEJMc2113092
PMID:: 34525293
: Opinia redakcyjna

Comment on: N Engl J Med. 2021 Jul 8;385(2):130-141. (PMID: 33891379)
Comment in: N Engl J Med. 2021 Sep 16;385(12):1150. (PMID: 34525294)

Informacja